Targeting MDM2-p53 interaction for cancer therapy: Are we there yet?

Current Medicinal Chemistry

Volumn 21, Issue 5, 2014, Pages 553-574

  Nag, S ^a   Zhang, X ^a   Srivenugopal, K S ^a   Wang, M H ^a   Wang, Wei ^a   Zhang, Ruiwen ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Drug target; MDM2; MDM2 p53 interaction; P53; Small molecule inhibitor

Indexed keywords

IMIDAZOLINE DERIVATIVE; NUTLIN 3; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; SPIROXINDOLE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; CELL ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEEDBACK SYSTEM; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; MULTICENTER STUDY (TOPIC); NEGATIVE FEEDBACK; NEOPLASM; NONHUMAN; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN TARGETING; REGULATOR GENE; TARGET CELL; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMIDAZOLINES; INDOLES; NEOPLASMS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS C-MDM2; SMALL MOLECULE LIBRARIES; TRYPTAMINES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84893274453     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113206660325     Document Type: Article

References (306)

1. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell, 2011, 144(5), 646-674.
2. Weinstein, I.B.; Joe, A. Oncogene addiction. Cancer Res., 2008, 68(9), 3077-3080; discussion 3080.
3. Letai, A.G. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer, 2008, 8(2), 121-132.
4. Zhang, Z.; Li, M.; Rayburn, E.R.; Hill, D.L.; Zhang, R.; Wang, H. Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. Am. J. Pharmacogenomics, 2005, 5(3), 173-190.
5. Zilfou, J.T.; Lowe, S.W. Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol., 2009, 1(5), a001883.
6. Levine, A.J.; Oren, M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer, 2009, 9(10), 749-758.
7. Meek, D.W. Tumour suppression by p53: a role for the DNA damage response? Nat. Rev. Cancer, 2009, 9(10), 714-723.
8. Teodoro, J.G.; Evans, S.K.; Green, M.R. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J. Mol. Med., 2007, 85(11), 1175-1186.
9. Vousden, K.H.; Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer, 2002, 2(8), 594-604.
10. Joerger, A.C.; Fersht, A.R. Structural biology of the tumor suppressor p53. Ann. Rev. Biochem., 2008, 77, 557-582.
11. Yoshida, K.; Miki, Y. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage. Cancer Sci., 2010, 101(4), 831-835.
12. Vazquez, A.; Bond, E.E.; Levine, A.J.; Bond, G.L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nature reviews. Drug Discov., 2008, 7(12), 979-987.
13. Riley, T.; Sontag, E.; Chen, P.; Levine, A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell. Biol., 2008, 9(5), 402-412.
14. Hainaut, P.; Hollstein, M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res., 2000, 77, 81-137.
15. Rivlin, N.; Brosh, R.; Oren, M.; Rotter, V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes & cancer, 2011, 2(4), 466-474.
16. Vousden, K.H.; Prives, C. Blinded by the Light: The Growing Complexity of p53. Cell, 2009, 137(3), 413-431.
17. Menendez, D.; Inga, A.; Resnick, M.A. The expanding universe of p53 targets. Nat. Rev. Cancer, 2009, 9(10), 724-737.
18. Momand, J.; Zambetti, G.P.; Olson, D.C.; George, D.; Levine, A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 1992, 69(7), 1237-1245.
19. Cahilly-Snyder, L.; Yang-Feng, T.; Francke, U.; George, D.L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet., 1987, 13(3), 235-244.
20. Fakharzadeh, S.S.; Trusko, S.P.; George, D.L. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBOJ., 1991, 10(6), 1565-1569.
21. Oliner, J.D.; Kinzler, K.W.; Meltzer, P.S.; George, D.L.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 1992, 358(6381), 80-83.
22. Olson, D.C.; Marechal, V.; Momand, J.; Chen, J.; Romocki, C.; Levine, A.J. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene, 1993, 8(9), 2353-2360.
23. Fang, S.; Jensen, J.P.; Ludwig, R.L.; Vousden, K.H.; Weissman, A.M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem., 2000, 275(12), 8945-8951.
24. Momand, J.; Jung, D.; Wilczynski, S.; Niland, J. The MDM2 gene amplification database. Nucleic Acids Res., 1998, 26(15), 3453-3459.
25. Onel, K.; Cordon-Cardo, C. MDM2 and prognosis. Mol. Cancer Res., 2004, 2(1), 1-8.
26. Rayburn, E.; Zhang, R.; He, J.; Wang, H. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets, 2005, 5(1), 27-41.
27. Beaudry, G.A.; Bertelsen, A.H.; Sherman, M.I. Therapeutic targeting of the p53 tumor suppressor gene. Curr. Opin. Biotechnol., 1996, 7(6), 592-600.
28. Mandinova, A.; Lee, S.W. The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci. Transl. Med., 2011, 3(64), 64rv61.
29. Ventura, A.; Kirsch, D.G.; McLaughlin, M.E.; Tuveson, D.A.; Grimm, J.; Lintault, L.; Newman, J.; Reczek, E.E.; Weissleder, R.; Jacks, T. Restoration of p53 function leads to tumour regression in vivo. Nature, 2007, 445(7128), 661-665.
30. Martins, C.P.; Brown-Swigart, L.; Evan, G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell, 2006, 127(7), 1323-1334.
31. Kastan, M.B. Wild-type p53: tumors can't stand it. Cell, 2007, 128(5), 837-840.
32. Wang, H.; Nan, L.; Yu, D.; Lindsey, J.R.; Agrawal, S.; Zhang, R. Anti-tumor efficacy of a novel antisense anti-MDM2 mixedbackbone oligonucleotide in human colon cancer models: p53- dependent and p53-independent mechanisms. Mol. Med., 2002, 8(4), 185-199.
33. Zhang; Wang, H. MDM2 oncogene as a novel target for human cancer therapy. Curr. Pharmaceut. Des., 2000, 6(4), 393-416.
34. Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer, 2003, 3(2), 102-109.
35. Montes de Oca Luna, R.; Wagner, D.S.; Lozano, G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature, 1995, 378(6553), 203-206.
36. de Rozieres, S.; Maya, R.; Oren, M.; Lozano, G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene, 2000, 19(13), 1691-1697.
37. Oliner, J.D.; Pietenpol, J.A.; Thiagalingam, S.; Gyuris, J.; Kinzler, K.W.; Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature, 1993, 362(6423), 857-860.
38. Cross, B.; Chen, L.; Cheng, Q.; Li, B.; Yuan, Z.M.; Chen, J. Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. J. Biol. Chem., 2011, 286(18), 16018-16029.
39. Thut, C.J.; Goodrich, J.A.; Tjian, R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev., 1997, 11(15), 1974-1986.
40. Bottger, A.; Bottger, V.; Garcia-Echeverria, C.; Chene, P.; Hochkeppel, H.K.; Sampson, W.; Ang, K.; Howard, S.F.; Picksley, S.M.; Lane, D.P. Molecular characterization of the hdm2-p53 interaction. J. Mol. Biol., 1997, 269(5), 744-756.
41. Kubbutat, M.H.; Jones, S.N.; Vousden, K.H. Regulation of p53 stability by Mdm2. Nature, 1997, 387(6630), 299-303.
42. Wsierska-Gadek, J.; Horky, M. How the nucleolar sequestration of p53 protein or its interplayers contributes to its (re)-activation. Ann. N. Y. Acad. Sci., 2003, 1010, 266-272.
43. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature, 1997, 387(6630), 296-299.
44. Honda, R.; Tanaka, H.; Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS. Lett., 1997, 420(1), 25-27.
45. Wu, X.; Bayle, J.H.; Olson, D.; Levine, A.J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev., 1993, 7(7A), 1126-1132.
46. Chi, S.W.; Lee, S.H.; Kim, D.H.; Ahn, M.J.; Kim, J.S.; Woo, J.Y.; Torizawa, T.; Kainosho, M.; Han, K.H. Structural details on mdm2-p53 interaction. J. Biol. Chem., 2005, 280(46), 38795-38802.
47. Poyurovsky, M.V.; Katz, C.; Laptenko, O.; Beckerman, R.; Lokshin, M.; Ahn, J.; Byeon, I.J.; Gabizon, R.; Mattia, M.; Zupnick, A.; Brown, L.M.; Friedler, A.; Prives, C. The C terminus of p53 binds the N-terminal domain of MDM2. Nat. Struct. Mol. Biol., 2010, 17(8), 982-989.
48. Nakamura, S.; Roth, J.A.; Mukhopadhyay, T. Multiple lysine mutations in the C-terminal domain of p53 interfere with MDM2- dependent protein degradation and ubiquitination. Mol. Cell. Biol., 2000, 20(24), 9391-9398.
49. Rodriguez, M.S.; Desterro, J.M.; Lain, S.; Lane, D.P.; Hay, R.T. Multiple C-terminal lysine residues target p53 for ubiquitinproteasome- mediated degradation. Mol. Cell. Biol., 2000, 20(22), 8458-8467.
50. Zhang, Y.; Lu, H. Signaling to p53: ribosomal proteins find their way. Cancer Cell., 2009, 16(5), 369-377.
51. Dai, M.S.; Lu, H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. Chem., 2004, 279(43), 44475-44482.
52. Zhang, Y.; Wolf, G.W.; Bhat, K.; Jin, A.; Allio, T.; Burkhart, W.A.; Xiong, Y. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol. Cell. Biol., 2003, 23(23), 8902-8912.
53. Dai, M.S.; Shi, D.; Jin, Y.; Sun, X.X.; Zhang, Y.; Grossman, S.R.; Lu, H. Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J. Biol. Chem., 2006, 281(34), 24304-24313.
54. Jin, A.; Itahana, K.; O'Keefe, K.; Zhang, Y. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol. Cell. Biol., 2004, 24(17), 7669-7680.
55. Dai, M.S.; Zeng, S.X.; Jin, Y.; Sun, X.X.; David, L.; Lu, H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol. Cell. Biol., 2004, 24(17), 7654-7668.
56. Zhang, Y.; Wang, J.; Yuan, Y.; Zhang, W.; Guan, W.; Wu, Z.; Jin, C.; Chen, H.; Zhang, L.; Yang, X.; He, F. Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26. Nucleic Acids Res., 2010, 38(19), 6544-6554.
57. Chen, D.; Zhang, Z.; Li, M.; Wang, W.; Li, Y.; Rayburn, E.R.; Hill, D.L.; Wang, H.; Zhang, R. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene, 2007, 26(35), 5029-5037.
58. Zhu, Y.; Poyurovsky, M.V.; Li, Y.; Biderman, L.; Stahl, J.; Jacq, X.; Prives, C. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol. Cell., 2009, 35(3), 316-326.
59. Zhou, X.; Hao, Q.; Liao, J.; Zhang, Q.; Lu, H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene, 2013, 32(3), 388-396.
60. Zhang, X.; Wang, W.; Wang, H.; Wang, M.H.; Xu, W.; Zhang, R. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop. Oncogene, 2013, 32(22), 2782-2791.
61. Sun, X.X.; DeVine, T.; Challagundla, K.B.; Dai, M.S. Interplay between ribosomal protein S27a and MDM2 protein in p53 activation in response to ribosomal stress. J. Biol. Chem., 2011, 286(26), 22730-22741.
62. Xiong, X.; Zhao, Y.; He, H.; Sun, Y., Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene, 2011, 30(15), 1798-1811.
63. Lohrum, M.A.; Ludwig, R.L.; Kubbutat, M.H.; Hanlon, M.; Vousden, K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell., 2003, 3(6), 577-587.
64. Zhang, Z.; Zhang, R. Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBOJ., 2008, 27(6), 852-864.
65. Wen, W.; Peng, C.; Kim, M.O.; Ho Jeong, C.; Zhu, F.; Yao, K.; Zykova, T.; Ma, W.; Carper, A.; Langfald, A.; Bode, A.M.; Dong, Z. Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability. Oncogene, 2013. doi: 10.1038/onc.2012.605. [Epub ahead of print]]
66. Su, W.J.; Fang, J.S.; Cheng, F.; Liu, C.; Zhou, F.; Zhang, J. RNF2/Ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development. Proc. Natl. Acad. Sci. U S A., 2013, 110(5), 1720-1725.
67. Chen, D.; Zhang, J.; Li, M.; Rayburn, E.R.; Wang, H.; Zhang, R. RYBP stabilizes p53 by modulating MDM2. EMBO Rep., 2009, 10(2), 166-172.
68. Kamijo, T.; Weber, J.D.; Zambetti, G.; Zindy, F.; Roussel, M.F.; Sherr, C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. U S A., 1998, 95(14), 8292-8297.
69. Honda, R.; Yasuda, H. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBOJ., 1999, 18(1), 22-27.
70. Weber, J.D.; Kuo, M.L.; Bothner, B.; DiGiammarino, E.L.; Kriwacki, R.W.; Roussel, M.F.; Sherr, C.J. Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. Mol. Cell. Biol., 2000, 20(7), 2517-2528.
71. Chen, D.; Kon, N.; Li, M.; Zhang, W.; Qin, J.; Gu, W. ARFBP1/ Mule is a critical mediator of the ARF tumor suppressor. Cell, 2005, 121(7), 1071-1083.
72. Louria-Hayon, I.; Grossman, T.; Sionov, R.V.; Alsheich, O.; Pandolfi, P.P.; Haupt, Y. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J. Biol. Chem., 2003, 278(35), 33134-33141.
73. Coutts, A.S.; Boulahbel, H.; Graham, A.; La Thangue, N.B. Mdm2 targets the p53 transcription cofactor JMY for degradation. EMBO Rep., 2007, 8(1), 84-90.
74. Yang, H.Y.; Wen, Y.Y.; Chen, C.H.; Lozano, G.; Lee, M.H. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol. Cell. Biol., 2003, 23(20), 7096-7107.
75. Shvarts, A.; Steegenga, W.T.; Riteco, N.; van Laar, T.; Dekker, P.; Bazuine, M.; van Ham, R.C.; van der Houven van Oordt, W.; Hate-Hateboer, G.; van der Eb, A.J.; Jochemsen, A.G. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J., 1996, 15(19), 5349-5357.
76. Zdzalik, M.; Pustelny, K.; Kedracka-Krok, S.; Huben, K.; Pecak, A.; Wladyka, B.; Jankowski, S.; Dubin, A.; Potempa, J.; Dubin, G. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73. Cell Cycle, 2010, 9(22), 4584-4591.
77. Danovi, D.; Meulmeester, E.; Pasini, D.; Migliorini, D.; Capra, M.; Frenk, R.; de Graaf, P.; Francoz, S.; Gasparini, P.; Gobbi, A.; Helin, K.; Pelicci, P.G.; Jochemsen, A.G.; Marine, J.C. Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell. Biol., 2004, 24(13), 5835-5843.
78. Prodosmo, A.; Giglio, S.; Moretti, S.; Mancini, F.; Barbi, F.; Avenia, N.; Di Conza, G.; Schunemann, H.J.; Pistola, L.; Ludovini, V.; Sacchi, A.; Pontecorvi, A.; Puxeddu, E.; Moretti, F. Analysis of human MDM4 variants in papillary thyroid carcinomas reveals new potential markers of cancer properties. J. Mol. Med., 2008, 86(5), 585-596.
79. Huang, L.; Yan, Z.; Liao, X.; Li, Y.; Yang, J.; Wang, Z.G.; Zuo, Y.; Kawai, H.; Shadfan, M.; Ganapathy, S.; Yuan, Z.M. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc. Natl. Acad. Sci. U S A., 2011, 108(29), 12001-12006.
80. Francoz, S.; Froment, P.; Bogaerts, S.; De Clercq, S.; Maetens, M.; Doumont, G.; Bellefroid, E.; Marine, J.C. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. U S A., 2006, 103(9), 3232-3237.
81. Tanimura, S.; Ohtsuka, S.; Mitsui, K.; Shirouzu, K.; Yoshimura, A.; Ohtsubo, M. MDM2 interacts with MDMX through their RING finger domains. FEBS Lett., 1999, 447(1), 5-9.
82. Shadfan, M.; Lopez-Pajares, V.; Yuan, Z.M. MDM2 and MDMX: Alone and together in regulation of p53. Transl. Cancer Res., 2012, 1(2), 88-89.
83. Marine, J.C.; Jochemsen, A.G. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun., 2005, 331(3), 750-760.
84. Marine, J.C.; Jochemsen, A.G. Mdmx and Mdm2: brothers in arms? Cell Cycle, 2004, 3(7), 900-904.
85. Pazgier, M.; Liu, M.; Zou, G.; Yuan, W.; Li, C.; Li, C.; Li, J.; Monbo, J.; Zella, D.; Tarasov, S.G.; Lu, W. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc. Natl. Acad. Sci. U S A., 2009, 106(12), 4665-4670.
86. Eischen, C.M.; Weber, J.D.; Roussel, M.F.; Sherr, C.J.; Cleveland, J.L. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev., 1999, 13(20), 2658-2669.
87. Kurki, S.; Peltonen, K.; Latonen, L.; Kiviharju, T.M.; Ojala, P.M.; Meek, D.; Laiho, M. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell, 2004, 5(5), 465-475.
88. Di Stefano, V.; Blandino, G.; Sacchi, A.; Soddu, S.; D'Orazi, G. HIPK2 neutralizes MDM2 inhibition rescuing p53 transcriptional activity and apoptotic function. Oncogene, 2004, 23(30), 5185-5192.
89. Alsheich-Bartok, O.; Haupt, S.; Alkalay-Snir, I.; Saito, S.; Appella, E.; Haupt, Y. PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene, 2008, 27(26), 3653-3661.
90. Bernardi, R.; Scaglioni, P.P.; Bergmann, S.; Horn, H.F.; Vousden, K.H.; Pandolfi, P.P. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat. Cell Biol., 2004, 6(7), 665-672.
91. Kurki, S.; Latonen, L.; Laiho, M. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J. Cell. Sci., 2003, 116(Pt 19), 3917-3925.
92. Gottifredi, V.; Prives, C. P53 and PML: new partners in tumor suppression. Trend. Cell Biol., 2001, 11(5), 184-187.
93. Linares, L.K.; Kiernan, R.; Triboulet, R.; Chable-Bessia, C.; Latreille, D.; Cuvier, O.; Lacroix, M.; Le Cam, L.; Coux, O.; Benkirane, M. Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat. Cell Biol., 2007, 9(3), 331-338.
94. Jin, Y.; Zeng, S.X.; Dai, M.S.; Yang, X.J.; Lu, H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J. Biol. Chem., 2002, 277(34), 30838-30843.
95. Nishida, T.; Yamada, Y. The nucleolar SUMO-specific protease SMT3IP1/SENP3 attenuates Mdm2-mediated p53 ubiquitination and degradation. Biochem. Biophys. Res. Commun., 2011, 406(2), 285-291.
96. Kim, J.W.; Song, P.I.; Jeong, M.H.; An, J.H.; Lee, S.Y.; Jang, S.M.; Song, K.H.; Armstrong, C.A.; Choi, K.H. TIP60 represses transcriptional activity of p73beta via an MDM2-bridged ternary complex. J. Biol. Chem., 2008, 283(29), 20077-20086.
97. Tang, Y.; Luo, J.; Zhang, W.; Gu, W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell., 2006, 24(6), 827-839.
98. Legube, G.; Linares, L.K.; Lemercier, C.; Scheffner, M.; Khochbin, S.; Trouche, D. Tip60 is targeted to proteasome-mediated degradation by Mdm2 and accumulates after UV irradiation. EMBOJ., 2002, 21(7), 1704-1712.
99. Oliver, T.G.; Meylan, E.; Chang, G.P.; Xue, W.; Burke, J.R.; Humpton, T.J.; Hubbard, D.; Bhutkar, A.; Jacks, T. Caspase-2- mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol. Cell., 2011, 43(1), 57-71.
100. Pan, W.; Issaq, S.; Zhang, Y., The in vivo role of the RP-Mdm2- p53 pathway in signaling oncogenic stress induced by pRb inactivation and Ras overexpression. Plos One, 2011, 6(6), e21625.
101. Mathew, R.; Arora, S.; Khanna, R.; Mathur, M.; Shukla, N.K.; Ralhan, R. Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur. J. Cancer, 2002, 38(6), 832-841.
102. Bae, S.; Jung, J.H.; An, I.S.; Kim, O.Y.; Lee, M.J.; Lee, J.H.; Park, I.C.; Lee, S.J.; An, S. TRIAD1 is negatively regulated by the MDM2 E3 ligase. Oncology reports, 2012, 28, (5), 1924-1928.
103. Bae, S.; Jung, J.H.; Kim, K.; An, I.S.; Kim, S.Y.; Lee, J.H.; Park, I.C.; Jin, Y.W.; Lee, S.J.; An, S., TRIAD1 inhibits MDM2- mediated p53 ubiquitination and degradation. FEBS. Lett., 2012, 586(19), 3057-3063.
104. Hsueh, K.W.; Fu, S.L.; Chang, C.B.; Chang, Y.L.; Lin, C.H. A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2. Biochim. Biophys. Acta, 2013, 1834(2), 508-515.
105. Yu, W.; Qiu, Z.; Gao, N.; Wang, L.; Cui, H.; Qian, Y.; Jiang, L.; Luo, J.; Yi, Z.; Lu, H.; Li, D.; Liu, M. PAK1IP1, a ribosomal stress-induced nucleolar protein, regulates cell proliferation via the p53-MDM2 loop. Nucleic Acids Res., 2011, 39(6), 2234-2248.
106. Kubo, N.; Wu, D.; Yoshihara, Y.; Sang, M.; Nakagawara, A.; Ozaki, T. Co-chaperon DnaJC7/TPR2 enhances p53 stability and activity through blocking the complex formation between p53 and MDM2. Biochem. Biophys. Res. Commun., 2013, 430(3), 1034-1039.
107. Sun, X.X.; Challagundla, K.B.; Dai, M.S. Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBOJ., 2012, 31(3), 576-592.
108. ElSawy, K.M.; Verma, C.S.; Joseph, T.L.; Lane, D.P.; Twarock, R.; Caves, L.S. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study. Cell Cycle, 2013, 12(3), 394-404.
109. Wade, M.; Li, Y.C.; Wahl, G.M. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer, 2013, 13(2), 83-96.
110. Xia, M.; Knezevic, D.; Tovar, C.; Huang, B.; Heimbrook, D.C.; Vassilev, L.T. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle, 2008, 7(11), 1604-1612.
111. Jiang, M.; Chiu, S.Y.; Hsu, W. SUMO-specific protease 2 in Mdm2-mediated regulation of p53. Cell Death Differ., 2011, 18(6), 1005-1015.
112. Jung, C.R.; Lim, J.H.; Choi, Y.; Kim, D.G.; Kang, K.J.; Noh, S.M.; Im, D.S. Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J. Clin. Invest., 2010, 120(12), 4493-4506.
113. Gronroos, E.; Terentiev, A.A.; Punga, T.; Ericsson, J. YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. Proc. Natl. Acad. Sci. U S A., 2004, 101(33), 12165-12170.
114. Sui, G.; Affar el, B.; Shi, Y.; Brignone, C.; Wall, N.R.; Yin, P.; Donohoe, M.; Luke, M.P.; Calvo, D.; Grossman, S.R.; Shi, Y. Yin Yang 1 is a negative regulator of p53. Cell, 2004, 117(7), 859-872.
115. Cummins, J.M.; Vogelstein, B. HAUSP is required for p53 destabilization. Cell Cycle, 2004, 3(6), 689-692.
116. Ding, B.; Sun, Y.; Huang, J. Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation. J. Biol. Chem., 2012, 287(18), 14621-14630.
117. Du, W.; Jiang, P.; Li, N.; Mei, Y.; Wang, X.; Wen, L.; Yang, X.; Wu, M. Suppression of p53 activity by Siva1. Cell Death Dffer., 2009, 16(11), 1493-1504.
118. Alt, J.R.; Greiner, T.C.; Cleveland, J.L.; Eischen, C.M. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBOJ., 2003, 22(6), 1442-1450.
119. Jones, S.N.; Hancock, A.R.; Vogel, H.; Donehower, L.A.; Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. U S A., 1998, 95(26), 15608-15612.
120. Zhang, Z.; Wang, H.; Li, M.; Rayburn, E.; Agrawal, S.; Zhang, R. Novel MDM2 p53-independent functions identified through RNA silencing technologies. Ann. N. Y. Acad. Sci., 2005, 1058, 205-214.
121. Manfredi, J.J. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev., 2010, 24(15), 1580-1589.
122. Ganguli, G.; Wasylyk, B. p53-independent functions of MDM2. Mol. Cancer Res., 2003, 1(14), 1027-1035.
123. Bouska, A.; Eischen, C.M. Murine double minute 2: p53- independent roads lead to genome instability or death. Trend. Biochem Sci., 2009, 34(6), 279-286.
124. Maguire, M.; Nield, P.C.; Devling, T.; Jenkins, R.E.; Park, B.K.; Polanski, R.; Vlatkovic, N.; Boyd, M.T. MDM2 regulates dihydrofolate reductase activity through monoubiquitination. Cancer Res., 2008, 68(9), 3232-3242.
125. Alt, J.R.; Bouska, A.; Fernandez, M.R.; Cerny, R.L.; Xiao, H.; Eischen, C.M. Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J. Biol. Chem., 2005, 280(19), 18771-18781.
126. Zhang, Z.; Wang, H.; Li, M.; Agrawal, S.; Chen, X.; Zhang, R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem., 2004, 279(16), 16000-16006.
127. Jin, Y.; Lee, H.; Zeng, S.X.; Dai, M.S.; Lu, H. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBOJ., 2003, 22(23), 6365-6377.
128. Xu, H.; Zhang, Z.; Li, M.; Zhang, R. MDM2 promotes proteasomal degradation of p21Waf1 via a conformation change. J. Biol. Chem., 2010, 285(24), 18407-18414.
129. Xiao, Z.X.; Chen, J.; Levine, A.J.; Modjtahedi, N.; Xing, J.; Sellers, W.R.; Livingston, D.M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature, 1995, 375(6533), 694-698.
130. Sun, P.; Dong, P.; Dai, K.; Hannon, G.J.; Beach, D. p53- independent role of MDM2 in TGF-beta1 resistance. Science, 1998, 282(5397), 2270-2272.
131. Lundgren, K.; Montes de Oca Luna, R.; McNeill, Y.B.; Emerick, E.P.; Spencer, B.; Barfield, C.R.; Lozano, G.; Rosenberg, M.P.; Finlay, C.A. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev., 1997, 11(6), 714-725.
132. Tang, Y.A.; Lin, R.K.; Tsai, Y.T.; Hsu, H.S.; Yang, Y.C.; Chen, C.Y.; Wang, Y.C. MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer. Clin. Cancer Res., 2012, 18(16), 4325-4333.
133. Loughran, O.; La Thangue, N.B. Apoptotic and growth-promoting activity of E2F modulated by MDM2. Mol. Cell. Biol., 2000, 20(6), 2186-2197.
134. Malaguarnera, R.; Vella, V.; Pandini, G.; Sanfilippo, M.; Pezzino, V.; Vigneri, R.; Frasca, F. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation. Mol. Cancer Res., 2008, 6(1), 64-77.
135. Fu, W.; Ma, Q.; Chen, L.; Li, P.; Zhang, M.; Ramamoorthy, S.; Nawaz, Z.; Shimojima, T.; Wang, H.; Yang, Y.; Shen, Z.; Zhang, Y.; Zhang, X.; Nicosia, S.V.; Zhang, Y.; Pledger, J.W.; Chen, J.; Bai, W. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J. Biol. Chem., 2009, 284(21), 13987-14000.
136. Zeng, X.; Chen, L.; Jost, C.A.; Maya, R.; Keller, D.; Wang, X.; Kaelin, W.G., Jr.; Oren, M.; Chen, J.; Lu, H. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol., 1999, 19(5), 3257-3266.
137. Yang, J.Y.; Zong, C.S.; Xia, W.; Yamaguchi, H.; Ding, Q.; Xie, X.; Lang, J.Y.; Lai, C.C.; Chang, C.J.; Huang, W.C.; Huang, H.; Kuo, H.P.; Lee, D.F.; Li, L.Y.; Lien, H.C.; Cheng, X.; Chang, K.J.; Hsiao, C.D.; Tsai, F.J.; Tsai, C.H.; Sahin, A.A.; Muller, W.J.; Mills, G.B.; Yu, D.; Hortobagyi, G.N.; Hung, M.C. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat. Cell. Biol., 2008, 10(2), 138-148.
138. Gu, L.; Zhu, N.; Zhang, H.; Durden, D.L.; Feng, Y.; Zhou, M. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell., 2009, 15(5), 363-375.
139. Nieminen, A.L.; Qanungo, S.; Schneider, E.A.; Jiang, B.H.; Agani, F.H. Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. J. Cell. Physiol., 2005, 204(2), 364-369.
140. Ravi, R.; Mookerjee, B.; Bhujwalla, Z.M.; Sutter, C.H.; Artemov, D.; Zeng, Q.; Dillehay, L.E.; Madan, A.; Semenza, G.L.; Bedi, A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev., 2000, 14(1), 34-44.
141. Carroll, V.A.; Ashcroft, M. Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res., 2008, 68(2), 545-552.
142. Yang, J.Y.; Zong, C.S.; Xia, W.; Wei, Y.; Ali-Seyed, M.; Li, Z.; Broglio, K.; Berry, D.A.; Hung, M.C. MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol. Cell. Biol., 2006, 26(19), 7269-7282.
143. Iwakuma, T.; Agarwal, N. MDM2 binding protein, a novel metastasis suppressor. Cancer Metas. Rev., 2012, 31(3-4), 633-640.
144. Jung, C.H.; Kim, J.; Park, J.K.; Hwang, S.G.; Moon, S.K.; Kim, W.J.; Um, H.D. Mdm2 increases cellular invasiveness by binding to and stabilizing the Slug mRNA. Cancer Lett., 2013, 335(2), 270-277.
145. Kurokawa, M.; Kim, J.; Geradts, J.; Matsuura, K.; Liu, L.; Ran, X.; Xia, W.; Ribar, T.J.; Henao, R.; Dewhirst, M.W.; Kim, W.J.; Lucas, J.E.; Wang, S.; Spector, N.L.; Kornbluth, S. A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53. Sci. Signal., 2013, 6(274), ra32.
146. Gu, L.; Findley, H.W.; Zhou, M. MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. Blood, 2002, 99(9), 3367-3375.
147. Rayburn, E.R.; Ezell, S.J.; Zhang, R. Recent advances in validating MDM2 as a cancer target. Anti-Cancer Agent. Med. Chem., 2009, 9(8), 882-903.
148. Lukas, J.; Gao, D.Q.; Keshmeshian, M.; Wen, W.H.; Tsao-Wei, D.; Rosenberg, S.; Press, M.F. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res., 2001, 61(7), 3212-3219.
149. Sjostrom, J.; Blomqvist, C.; Heikkila, P.; Boguslawski, K.V.; Raisanen-Sokolowski, A.; Bengtsson, N.O.; Mjaaland, I.; Malmstrom, P.; Ostenstadt, B.; Bergh, J.; Wist, E.; Valvere, V.; Saksela, E. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin. Cancer Res., 2000, 6(8), 3103-3110.
150. Osman, I.; Drobnjak, M.; Fazzari, M.; Ferrara, J.; Scher, H.I.; Cordon-Cardo, C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin. Cancer Res., 1999, 5(8), 2082-2088.
151. Leite, K.R.; Franco, M.F.; Srougi, M.; Nesrallah, L.J.; Nesrallah, A.; Bevilacqua, R.G.; Darini, E.; Carvalho, C.M.; Meirelles, M.I.; Santana, I.; Camara-Lopes, L.H. Abnormal expression of MDM2 in prostate carcinoma. Mod. Pathol., 2001, 14(5), 428-436.
152. Khor, L.Y.; Desilvio, M.; Al-Saleem, T.; Hammond, M.E.; Grignon, D.J.; Sause, W.; Pilepich, M.; Okunieff, P.; Sandler, H.; Pollack, A.; Radiation Therapy Oncology, G. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer, 2005, 104(5), 962-967.
153. Dworakowska, D.; Jassem, E.; Jassem, J.; Karmolinski, A.; Dworakowski, R.; Wirth, T.; Gruchala, M.; Rynkiewicz, A.; Skokowski, J.; Yla-Herttuala, S.; Jaskiewicz, K.; Czestochowska, E. Clinical significance of apoptotic index in non-small cell lung cancer: correlation with p53, mdm2, pRb and p21WAF1/CIP1 protein expression. J. Cancer Res. Clin. Oncol., 2005, 131(9), 617-623.
154. Mori, S.; Ito, G.; Usami, N.; Yoshioka, H.; Ueda, Y.; Kodama, Y.; Takahashi, M.; Fong, K.M.; Shimokata, K.; Sekido, Y. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer, 2004, 100(8), 1673-1682.
155. Higashiyama, M.; Doi, O.; Kodama, K.; Yokouchi, H.; Kasugai, T.; Ishiguro, S.; Takami, K.; Nakayama, T.; Nishisho, I. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Brit. J. Cancer, 1997, 75(9), 1302-1308.
156. Abdel-Fattah, G.; Yoffe, B.; Krishnan, B.; Khaoustov, V.; Itani, K. MDM2/p53 protein expression in the development of colorectal adenocarcinoma. J. Gastrointest. Surg., 2000, 4(1), 109-114.
157. Elkablawy, M.A.; Maxwell, P.; Williamson, K.; Anderson, N.; Hamilton, P.W. Apoptosis and cell-cycle regulatory proteins in colorectal carcinoma: relationship to tumour stage and patient survival. J. Pathol., 2001, 194(4), 436-443.
158. Takata, O.; Kawamura, Y.J.; Konishi, F.; Sasaki, J.; Kai, T.; Miyakura, Y.; Nagai, H.; Tsukamoto, T. cDNA array analysis for prediction of hepatic metastasis of colorectal carcinoma. Surgery Today, 2006, 36(7), 608-614.
159. Paradiso, A.; Ranieri, G.; Simone, G.; Silvestris, N.; Costa, A.; De Lena, M.; Leone, A.; Vallejo, C.; Lacava, J. mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer. Oncology, 2002, 62(3), 278-285.
160. Cescon, D.W.; Bradbury, P.A.; Asomaning, K.; Hopkins, J.; Zhai, R.; Zhou, W.; Wang, Z.; Kulke, M.; Su, L.; Ma, C.; Xu, W.; Marshall, A.L.; Heist, R.S.; Wain, J.C.; Lynch, T.J., Jr.; Christiani, D.C.; Liu, G. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin. Cancer Res., 2009, 15(9), 3103-3109.
161. Okamoto, H.; Fujishima, F.; Nakamura, Y.; Zuguchi, M.; Miyata, G.; Kamei, T.; Nakano, T.; Katsura, K.; Abe, S.; Taniyama, Y.; Teshima, J.; Watanabe, M.; Sato, A.; Ohuchi, N.; Sasano, H. Murine double minute 2 and its association with chemoradioresistance of esophageal squamous cell carcinoma. Anticancer Res., 2013, 33(4), 1463-1471.
162. Ladanyi, M.; Cha, C.; Lewis, R.; Jhanwar, S.C.; Huvos, A.G.; Healey, J.H. MDM2 gene amplification in metastatic osteosarcoma. Cancer res., 1993, 53(1), 16-18.
163. Ito, M.; Barys, L.; O'Reilly, T.; Young, S.; Gorbatcheva, B.; Monahan, J.; Zumstein-Mecker, S.; Choong, P.F.; Dickinson, I.; Crowe, P.; Hemmings, C.; Desai, J.; Thomas, D.M.; Lisztwan, J. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Clin. Cancer Res., 2011, 17(3), 416-426.
164. Terry, K.; McGrath, M.; Lee, I.M.; Buring, J.; De Vivo, I. MDM2 SNP309 is associated with endometrial cancer risk. Cancer Epidemiol. Biomarkers Prev., 2008, 17(4), 983-986.
165. Ye, Y.; Li, X.; Yang, J.; Miao, S.; Wang, S.; Chen, Y.; Xia, X.; Wu, X.; Zhang, J.; Zhou, Y.; He, S.; Tan, Y.; Qiang, F.; Li, G.; Roe, O.D.; Zhou, J. MDM2 is a useful prognostic biomarker for resectable gastric cancer. Cancer Sci., 2013, 104(5), 590-598.
166. Asomaning, K.; Reid, A.E.; Zhou, W.; Heist, R.S.; Zhai, R.; Su, L.; Kwak, E.L.; Blaszkowsky, L.; Zhu, A.X.; Ryan, D.P.; Christiani, D.C.; Liu, G. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin. Cancer Res., 2008, 14(12), 4010-4015.
167. Baekelandt, M.; Kristensen, G.B.; Nesland, J.M.; Trope, C.G.; Holm, R. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J. Clin. Oncol., 1999, 17(7), 2061.
168. Ma, Y.Y.; Guan, T.P.; Yao, H.B.; Yu, S.; Chen, L.G.; Xia, Y.J.; He, X.J.;
169. Onat, O.E.; Tez, M.; Ozcelik, T.; Toruner, G.A. MDM2 T309G polymorphism is associated with bladder cancer. Anticancer Res., 2006, 26(5A), 3473-3475.
170. Lianes, P.; Orlow, I.; Zhang, Z.F.; Oliva, M.R.; Sarkis, A.S.; Reuter, V.E.; Cordon-Cardo, C. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J. Natl. Cancer Inst., 1994, 86(17), 1325-1330.
171. Watanabe, T.; Ichikawa, A.; Saito, H.; Hotta, T. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk. Lymphoma, 1996, 21(5-6), 391-397, color plates XVI following 395.
172. Gustafsson, B.; Axelsson, B.; Gustafsson, B.; Christensson, B.; Winiarski, J. MDM2 and p53 in childhood acute lymphoblastic leukemia: higher expression in childhood leukemias with poor prognosis compared to long-term survivors. Pediatr. Hematol. Oncol., 2001, 18(8), 497-508.
173. Gryshchenko, I.; Hofbauer, S.; Stoecher, M.; Daniel, P.T.; Steurer, M.; Gaiger, A.; Eigenberger, K.; Greil, R.; Tinhofer, I. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J. Clin. Oncol., 2008, 26(14), 2252-2257.
174. Muthusamy, V.; Hobbs, C.; Nogueira, C.; Cordon-Cardo, C.; McKee, P.H.; Chin, L.; Bosenberg, M.W. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer, 2006, 45(5), 447-454.
175. Polsky, D.; Bastian, B.C.; Hazan, C.; Melzer, K.; Pack, J.; Houghton, A.; Busam, K.; Cordon-Cardo, C.; Osman, I. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer res., 2001, 61(20), 7642-7646.
176. Rajabi, P.; Karimian, P.; Heidarpour, M. The relationship between MDM2 expression and tumor thickness and invasion in primary cutaneous malignant melanoma. J. Res. Med. Sci., 2012, 17(5), 452-455.
177. Firoz, E.F.; Warycha, M.; Zakrzewski, J.; Pollens, D.; Wang, G.; Shapiro, R.; Berman, R.; Pavlick, A.; Manga, P.; Ostrer, H.; Celebi, J.T.; Kamino, H.; Darvishian, F.; Rolnitzky, L.; Goldberg, J.D.; Osman, I.; Polsky, D. Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma. Clin. Cancer Res., 2009, 15(7), 2573-2580.
178. Coupland, S.E.; Anastassiou, G.; Stang, A.; Schilling, H.; Anagnostopoulos, I.; Bornfeld, N.; Stein, H. The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma. J. Pathol., 2000, 191(2), 120-126.
179. Dworakowska, D.; Jassem, E.; Jassem, J.; Peters, B.; Dziadziuszko, R.; Zylicz, M.; Jakobkiewicz-Banecka, J.; Kobierska-Gulida, G.; Szymanowska, A.; Skokowski, J.; Roessner, A.; Schneider-Stock, R. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer, 2004, 43(3), 285-295.
180. Grochola, L.F.; Zeron-Medina, J.; Meriaux, S.; Bond, G.L. Singlenucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb. Perspect. Biol., 2010, 2(5), a001032.
181. Bond, G.L.; Hu, W.; Bond, E.E.; Robins, H.; Lutzker, S.G.; Arva, N.C.; Bargonetti, J.; Bartel, F.; Taubert, H.; Wuerl, P.; Onel, K.; Yip, L.; Hwang, S.J.; Strong, L.C.; Lozano, G.; Levine, A.J. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 2004, 119(5), 591-602.
182. Bond, G.L.; Hirshfield, K.M.; Kirchhoff, T.; Alexe, G.; Bond, E.E.; Robins, H.; Bartel, F.; Taubert, H.; Wuerl, P.; Hait, W.; Toppmeyer, D.; Offit, K.; Levine, A.J. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res., 2006, 66(10), 5104-5110.
183. Wan, Y.; Wu, W.; Yin, Z.; Guan, P.; Zhou, B. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated metaanalysis. BMC Cancer, 2011, 11, 208.
184. Wilkening, S.; Bermejo, J.L.; Hemminki, K. MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis, 2007, 28(11), 2262-2267.
185. El Hallani, S.; Marie, Y.; Idbaih, A.; Rodero, M.; Boisselier, B.; Laigle-Donadey, F.; Ducray, F.; Delattre, J.Y.; Sanson, M. No association of MDM2 SNP309 with risk of glioblastoma and prognosis. J. Neurooncol., 2007, 85(3), 241-244.
186. Araki, S.; Eitel, J.A.; Batuello, C.N.; Bijangi-Vishehsaraei, K.; Xie, X.J.; Danielpour, D.; Pollok, K.E.; Boothman, D.A.; Mayo, L.D. TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J. Clin. Invest., 2010, 120(1), 290-302.
187. Phelps, M.; Darley, M.; Primrose, J.N.; Blaydes, J.P. p53- independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Res., 2003, 63(10), 2616-2623.
188. Brekman, A.; Singh, K.E.; Polotskaia, A.; Kundu, N.; Bargonetti, J. A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res., 2011, 13(1), R3.
189. Zhou, M.; Gu, L.; Findley, H.W.; Jiang, R.; Woods, W.G. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells. Cancer Res., 2003, 63(19), 6357-6362.
190. Carr, J.; Bell, E.; Pearson, A.D.; Kees, U.R.; Beris, H.; Lunec, J.; Tweddle, D.A. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res., 2006, 66(4), 2138-2145.
191. Liu, W.; He, L.; Ramirez, J.; Ratain, M.J. Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells. Clin. Cancer Res., 2009, 15(24), 7602-7607.
192. Zhang, R.; Wang, H.; Agrawal, S. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr. Cancer Drug Targets, 2005, 5(1), 43-49.
193. Wang, H.; Nan, L.; Yu, D.; Agrawal, S.; Zhang, R. Antisense anti- MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res., 2001, 7(11), 3613-3624.
194. Zhang, Z.; Li, M.; Wang, H.; Agrawal, S.; Zhang, R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci. U S A., 2003, 100(20), 11636-11641.
195. Zhang, Z.; Wang, H.; Prasad, G.; Li, M.; Yu, D.; Bonner, J.A.; Agrawal, S.; Zhang, R. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin. Cancer Res., 2004, 10(4), 1263-1273.
196. Zhang, R.; Wang, H. Antisense oligonucleotide inhibitors of MDM2 oncogene expression. Met. Mol. Med., 2003, 85, 205-222.
197. Wang, H.; Zeng, X.; Oliver, P.; Le, L.P.; Chen, J.; Chen, L.; Zhou, W.; Agrawal, S.; Zhang, R. MDM2 oncogene as a target for cancer therapy: An antisense approach. Int. J. Oncol., 1999, 15(4), 653-660.
198. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004, 303(5659), 844-848.
199. Fry, D.C.; Vassilev, L.T. Targeting protein-protein interactions for cancer therapy. J. Mol. Med., 2005, 83(12), 955-963.
200. Vassilev, L.T. MDM2 inhibitors for cancer therapy. Trends Mol. Med., 2007, 13(1), 23-31.
201. Chen, J.; Wang, J.; Xu, B.; Zhu, W.; Li, G. Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: molecular dynamics simulation and free energy analysis. J. Mol. Graphics Modell., 2011, 30, 46-53.
202. Shangary, S.; Wang, S. Small-molecule inhibitors of the MDM2- p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Ann. Rev. Pharmacol. Toxicol., 2009, 49, 223-241.
203. Kussie, P.H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A.J.; Pavletich, N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 1996, 274(5289), 948-953.
204. Chen, L.; Agrawal, S.; Zhou, W.; Zhang, R.; Chen, J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. U S A., 1998, 95(1), 195-200.
205. Tortora, G.; Caputo, R.; Damiano, V.; Bianco, R.; Chen, J.; Agrawal, S.; Bianco, A.R.; Ciardiello, F. A novel MDM2 antisense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int. J. Cancer, 2000, 88(5), 804-809.
206. Wang, H.; Oliver, P.; Zhang, Z.; Agrawal, S.; Zhang, R. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann. N. Y. Acad. Sci., 2003, 1002, 217-235.
207. Castanotto, D.; Li, J.R.; Michienzi, A.; Langlois, M.A.; Lee, N.S.; Puymirat, J.; Rossi, J.J. Intracellular ribozyme applications. Biochem. Soc. Trans., 2002, 30(Pt 6), 1140-1145.
208. Brummelkamp, T.R.; Fabius, A.W.; Mullenders, J.; Madiredjo, M.; Velds, A.; Kerkhoven, R.M.; Bernards, R.; Beijersbergen, R.L. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol., 2006, 2(4), 202-206.
209. Brown, C.J.; Dastidar, S.G.; See, H.Y.; Coomber, D.W.; Ortiz-Lombardia, M.; Verma, C.; Lane, D.P. Rational design and biophysical characterization of thioredoxin-based aptamers: insights into peptide grafting. J. Mol. Biol., 2010, 395(4), 871-883.
210. Kenjo, E.; Asai, T.; Yonenaga, N.; Ando, H.; Ishii, T.; Hatanaka, K.; Shimizu, K.; Urita, Y.; Dewa, T.; Nango, M.; Tsukada, H.; Oku, N. Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy. Biol. Pharm. Bull., 2013, 36(2), 287-291.
211. Yu, H.; Zou, Y.; Jiang, L.; Yin, Q.; He, X.; Chen, L.; Zhang, Z.; Gu, W.; Li, Y. Induction of apoptosis in non-small cell lung cancer by downregulation of MDM2 using pH-responsive PMPC-b- PDPA/siRNA complex nanoparticles. Biomaterials, 2013, 34(11), 2738-2747.
212. Li, M.; Zhang, Z.; Hill, D.L.; Chen, X.; Wang, H.; Zhang, R. Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res., 2005, 65(18), 8200-8208.
213. Li, M.; Zhang, Z.; Hill, D.L.; Wang, H.; Zhang, R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res., 2007, 67(5), 1988-1996.
214. Wang, W.; Zhao, Y.; Rayburn, E.R.; Hill, D.L.; Wang, H.; Zhang, R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemoth. Pharm., 2007, 59(5), 589-601.
215. Qin, J.J.; Nag, S.; Voruganti, S.; Wang, W.; Zhang, R. Natural product MDM2 inhibitors: anticancer activity and mechanisms of action. Curr. Med. Chem., 2012, 19(33), 5705-5725.
216. Lauria, A.; Tutone, M.; Ippolito, M.; Pantano, L.; Almerico, A.M. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr. Med. Chem., 2010, 17(28), 3142-3154.
217. Sun, Y., Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol. Ther., 2003, 2(6), 623-629.
218. Yang, Y.; Ludwig, R.L.; Jensen, J.P.; Pierre, S.A.; Medaglia, M.V.; Davydov, I.V.; Safiran, Y.J.; Oberoi, P.; Kenten, J.H.; Phillips, A.C.; Weissman, A.M.; Vousden, K.H. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell, 2005, 7(6), 547-559.
219. Kitagaki, J.; Agama, K.K.; Pommier, Y.; Yang, Y.; Weissman, A.M. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol. Cancer Ther., 2008, 7(8), 2445-2454.
220. Kojima, K.; Burks, J.K.; Arts, J.; Andreeff, M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1- mediated apoptosis in acute myeloid and lymphoid leukemias. Mol. Cancer Ther., 2010, 9(9), 2545-2557.
221. Wang, W.; Hu, Y. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy. Med. Res. Rev., 2012, 32(6), 1159-1196.
222. Arkin, M.R.; Wells, J.A. Small-molecule inhibitors of proteinprotein interactions: progressing towards the dream. Nat. Rev. Drug Disco., 2004, 3(4), 301-317.
223. Kamal, A.; Mohammed, A.A.; Shaik, T.B. p53-Mdm2 inhibitors: patent review (2009-2010). Exp. Opin. Ther. Patents, 2012, 22(2), 95-105.
224. Millard, M.; Pathania, D.; Grande, F.; Xu, S.; Neamati, N. Smallmolecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Curr. Pharm. Des., 2011, 17(6), 536-559.
225. Zak, K.; Pecak, A.; Rys, B.; Wladyka, B.; Domling, A.; Weber, L.; Holak, T.A.; Dubin, G. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present). Exp. Opin. Ther. Patents, 2013, 23(4), 425-448.
226. Tovar, C.; Rosinski, J.; Filipovic, Z.; Higgins, B.; Kolinsky, K.; Hilton, H.; Zhao, X.; Vu, B.T.; Qing, W.; Packman, K.; Myklebost, O.; Heimbrook, D.C.; Vassilev, L.T. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. U S A., 2006, 103(6), 1888-1893.
227. Van Maerken, T.; Ferdinande, L.; Taildeman, J.; Lambertz, I.; Yigit, N.; Vercruysse, L.; Rihani, A.; Michaelis, M.; Cinatl, J., Jr.; Cuvelier, C.A.; Marine, J.C.; De Paepe, A.; Bracke, M.; Speleman, F.; Vandesompele, J. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wildtype p53. J. Natl. Cancer Inst., 2009, 101(22), 1562-1574.
228. Tabe, Y.; Sebasigari, D.; Jin, L.; Rudelius, M.; Davies-Hill, T.; Miyake, K.; Miida, T.; Pittaluga, S.; Raffeld, M. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin. Cancer Res., 2009, 15(3), 933-942.
229. Ohnstad, H.O.; Paulsen, E.B.; Noordhuis, P.; Berg, M.; Lothe, R.A.; Vassilev, L.T.; Myklebost, O. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer, 2011, 11, 211-211.
230. Hasegawa, H.; Yamada, Y.; Iha, H.; Tsukasaki, K.; Nagai, K.; Atogami, S.; Sugahara, K.; Tsuruda, K.; Ishizaki, A.; Kamihira, S. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia, 2009, 23(11), 2090-2101.
231. Tovar, C.; Higgins, B.; Kolinsky, K.; Xia, M.; Packman, K.; Heimbrook, D.C.; Vassilev, L.T. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol. Cancer, 2011, 10, 49.
232. Wang, J.; Zheng, T.; Chen, X.; Song, X.; Meng, X.; Bhatta, N.; Pan, S.; Jiang, H.; Liu, L. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro. J. Gastroenterol. Hepatol., 2011, 26(2), 371-377.
233. Kitagawa, M.; Aonuma, M.; Lee, S.H.; Fukutake, S.; McCormick, F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene, 2008, 27(40), 5303-5314.
234. Ambrosini, G.; Sambol, E.B.; Carvajal, D.; Vassilev, L.T.; Singer, S.; Schwartz, G.K. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene, 2007, 26(24), 3473-3481.
235. LaRusch, G.A.; Jackson, M.W.; Dunbar, J.D.; Warren, R.S.; Donner, D.B.; Mayo, L.D. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res., 2007, 67(2), 450-454.
236. Dey, A.; Wong, E.T.; Bist, P.; Tergaonkar, V.; Lane, D.P. Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy. Cell Cycle, 2007, 6(17), 2178-2185.
237. Impicciatore, G.; Sancilio, S.; Miscia, S.; Di Pietro, R. Nutlins and ionizing radiation in cancer therapy. Curr. Pharm. Des., 2010, 16(12), 1427-1442.
238. Jones, R.J.; Bjorklund, C.C.; Baladandayuthapani, V.; Kuhn, D.J.; Orlowski, R.Z. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol. Cancer Ther., 2012, 11(10), 2243-2253.
239. Wang, H.; Ma, X.; Ren, S.; Buolamwini, J.K.; Yan, C. A smallmolecule inhibitor of MDMX activates p53 and induces apoptosis. Mol. Cancer Ther., 2011, 10(1), 69-79.
240. Michaelis, M.; Rothweiler, F.; Klassert, D.; von Deimling, A.; Weber, K.; Fehse, B.; Kammerer, B.; Doerr, H.W.; Cinatl, J., Jr. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res., 2009, 69(2), 416-421.
241. Yu, S.; Qin, D.; Shangary, S.; Chen, J.; Wang, G.; Ding, K.; McEachern, D.; Qiu, S.; Nikolovska-Coleska, Z.; Miller, R.; Kang, S.; Yang, D.; Wang, S. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem., 2009, 52(24), 7970-7973.
242. Popowicz, G.M.; Czarna, A.; Wolf, S.; Wang, K.; Wang, W.; Domling, A.; Holak, T.A. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53- MDMX/MDM2 antagonist drug discovery. Cell Cycle, 2010, 9(6), 1104-1111.
243. Sosin, A.M.; Burger, A.M.; Siddiqi, A.; Abrams, J.; Mohammad, R.M.; Al-Katib, A.M. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant Bcell lymphomas. J. Hematol. Oncol., 2012, 5, 57.
244. Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R.S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R.B.; Pienta, K.J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U S A., 2008, 105(10), 3933-3938.
245. Zhao, Y.; Liu, L.; Sun, W.; Lu, J.; McEachern, D.; Li, X.; Yu, S.; Bernard, D.; Ochsenbein, P.; Ferey, V.; Carry, J.C.; Deschamps, J.R.; Sun, D.; Wang, S. Diastereomeric Spirooxindoles as Highly Potent and Efficacious MDM2 Inhibitors. J. Am. Chem. Soc., 2013, 135(19), 7223-7234.
246. Zhao, Y.; Yu, S.; Sun, W.; Liu, L.; Lu, J.; McEachern, D.; Shargary, S.; Bernard, D.; Li, X.; Zhao, T.; Zou, P.; Sun, D.; Wang, S. A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice. J. Med. Chem., 2013, Jun 20. {Epub ahead of print].
247. Hayashi, R.; Wang, D.; Hara, T.; Iera, J.A.; Durell, S.R.; Appella, D.H. N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53. Bioorg. Med. Chem., 2009, 17(23), 7884-7893.
248. Stoll, R.; Renner, C.; Hansen, S.; Palme, S.; Klein, C.; Belling, A.; Zeslawski, W.; Kamionka, M.; Rehm, T.; Muhlhahn, P.; Schumacher, R.; Hesse, F.; Kaluza, B.; Voelter, W.; Engh, R.A.; Holak, T.A. Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry, 2001, 40(2), 336-344.
249. Kumar, S.K.; Hager, E.; Pettit, C.; Gurulingappa, H.; Davidson, N.E.; Khan, S.R. Design, synthesis, and evaluation of novel boronic- chalcone derivatives as antitumor agents. J. Med. Chem., 2003, 46(14), 2813-2815.
250. Achanta, G.; Modzelewska, A.; Feng, L.; Khan, S.R.; Huang, P. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. Mol. Pharmacol., 2006, 70(1), 426-433.
251. Sun, X.X.; Dai, M.S.; Lu, H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem., 2007, 282(11), 8052-8059.
252. Rew, Y.; Sun, D.; Gonzalez-Lopez De Turiso, F.; Bartberger, M.D.; Beck, H.P.; Canon, J.; Chen, A.; Chow, D.; Deignan, J.; Fox, B.M.; Gustin, D.; Huang, X.; Jiang, M.; Jiao, X.; Jin, L.; Kayser, F.; Kopecky, D.J.; Li, Y.; Lo, M.C.; Long, A.M.; Michelsen, K.; Oliner, J.D.; Osgood, T.; Ragains, M.; Saiki, A.Y.; Schneider, S.; Toteva, M.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Medina, J.C.; Olson, S.H. Structure-based design of novel inhibitors of the MDM2-p53 interaction. J. Med. Chem., 2012, 55(11), 4936-4954.
253. Issaeva, N.; Bozko, P.; Enge, M.; Protopopova, M.; Verhoef, L.G.; Masucci, M.; Pramanik, A.; Selivanova, G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med., 2004, 10(12), 1321-1328.
254. Krajewski, M.; Ozdowy, P.; D'Silva, L.; Rothweiler, U.; Holak, T.A. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat. Med., 2005, 11(11), 1135-1136; author reply 1136-1137.
255. Roxburgh, P.; Hock, A.K.; Dickens, M.P.; Mezna, M.; Fischer, P.M.; Vousden, K.H. Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis, 2012, 33(4), 791-798.
256. Lane, D.P.; Cheok, C.F.; Lain, S. p53-based cancer therapy. Cold Spring Harb. Perspect. Biol., 2010, 2(9), a001222.
257. Sasiela, C.A.; Stewart, D.H.; Kitagaki, J.; Safiran, Y.J.; Yang, Y.; Weissman, A.M.; Oberoi, P.; Davydov, I.V.; Goncharova, E.; Beutler, J.A.; McMahon, J.B.; O'Keefe, B.R. Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen. J. Biomol. Screen., 2008, 13(3), 229-237.
258. Fang, J.; Xia, C.; Cao, Z.; Zheng, J.Z.; Reed, E.; Jiang, B.H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J., 2005, 19(3), 342-353.
259. Gopal, Y.N.; Chanchorn, E.; Van Dyke, M.W. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol. Cancer Ther., 2009, 8(3), 552-562.
260. Nasim, S.; Crooks, P.A. Antileukemic activity of aminoparthenolide analogs. Bioorg. Med. Chem. Lett., 2008, 18(14), 3870-3873.
261. Zhang, X.; Gu, L.; Li, J.; Shah, N.; He, J.; Yang, L.; Hu, Q.; Zhou, M. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res., 2010, 70(23), 9895-9904.
262. Nag, S.A.; Qin, J.J.; Wang, W.; Wang, M.H.; Wang, H.; Zhang, R. Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action. Front. Pharmacol., 2012, 3, 25.
263. Zhao, Y.; Wang, W.; Han, L.; Rayburn, E.R.; Hill, D.L.; Wang, H.; Zhang, R. Isolation, structural determination, and evaluation of the biological activity of 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol [20(S)-25-OCH3-PPD], a novel natural product from Panax notoginseng. Med. Chem., 2007, 3(1), 51-60.
264. Wang, W.; Wang, H.; Rayburn, E.R.; Zhao, Y.; Hill, D.L.; Zhang, R. 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Brit. J. Cancer, 2008, 98(4), 792-802.
265. Wang, W.; Rayburn, E.R.; Zhao, Y.; Wang, H.; Zhang, R. Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett., 2009, 278(2), 241-248.
266. Wang, W.; Rayburn, E.R.; Hang, J.; Zhao, Y.; Wang, H.; Zhang, R. Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer, 2009, 65(3), 306-311.
267. Wang, W.; Rayburn, E.R.; Hao, M.; Zhao, Y.; Hill, D.L.; Zhang, R.; Wang, H. Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate, 2008, 68(8), 809-819.
268. Shinkre, B.A.; Raisch, K.P.; Fan, L.; Velu, S.E. Analogs of the marine alkaloid makaluvamines: synthesis, topoisomerase II inhibition, and anticancer activity. Bioorg. Med. Chem. Lett., 2007, 17(10), 2890-2893.
269. Shinkre, B.A.; Raisch, K.P.; Fan, L.; Velu, S.E. Synthesis and antiproliferative activity of benzyl and phenethyl analogs of makaluvamines. Bioorg. Med. Chem., 2008, 16(5), 2541-2549.
270. Wang, W.; Rayburn, E.R.; Velu, S.E.; Nadkarni, D.H.; Murugesan, S.; Zhang, R. In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues. Clin. Cancer Res., 2009, 15(10), 3511-3518.
271. Chen, T.; Xu, Y.; Guo, H.; Liu, Y.; Hu, P.; Yang, X.; Li, X.; Ge, S.; Velu, S.E.; Nadkarni, D.H.; Wang, W.; Zhang, R.; Wang, H. Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action. Plos One, 2011, 6(6), e20729.
272. Wang, W.; Rayburn, E.R.; Velu, S.E.; Chen, D.; Nadkarni, D.H.; Murugesan, S.; Chen, D.; Zhang, R., A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action. Breast Cancer Res. Treat., 2010, 123(2), 321-331.
273. Nadkarni, D.H.; Wang, F.; Wang, W.; Rayburn, E.R.; Ezell, S.J.; Murugesan, S.; Velu, S.E.; Zhang, R. Synthesis and in vitro antilung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2- de]quinolin-8(1H)-one alkaloid analogs. Med. Chem., 2009, 5(3), 227-236.
274. Zhang, X.; Xu, H.; Zhang, X.; Voruganti, S.; Murugesan, S.; Nadkarni, D.H.; Velu, S.E.; Wang, M.H.; Wang, W.; Zhang, R. Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog. Marine Drug., 2012, 10(5), 1138-1155.
275. Secchiero, P.; Bosco, R.; Celeghini, C.; Zauli, G. Recent advances in the therapeutic perspectives of Nutlin-3. Curr. Pharm. Des., 2011, 17(6), 569-577.
276. Yuan, Y.; Liao, Y.M.; Hsueh, C.T.; Mirshahidi, H.R. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J. Hematol. Oncol., 2011, 4, 16.
277. Ray-Coquard, I.; Blay, J.Y.; Italiano, A.; Le Cesne, A.; Penel, N.; Zhi, J.; Heil, F.; Rueger, R.; Graves, B.; Ding, M.; Geho, D.; Middleton, S.A.; Vassilev, L.T.; Nichols, G.L.; Bui, B.N. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol., 2012, 13(11), 1133-1140.
278. Carol, H.; Reynolds, C.P.; Kang, M.H.; Keir, S.T.; Maris, J.M.; Gorlick, R.; Kolb, E.A.; Billups, C.A.; Geier, B.; Kurmasheva, R.T.; Houghton, P.J.; Smith, M.A.; Lock, R.B. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer, 2013, 60(4), 633-641.
279. Chargari, C.; Leteur, C.; Angevin, E.; Bashir, T.; Schoentjes, B.; Arts, J.; Janicot, M.; Bourhis, J.; Deutsch, E. Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts. Cancer Lett., 2011, 312(2), 209-218.
280. Smith, M.A.; Gorlick, R.; Kolb, E.A.; Lock, R.; Carol, H.; Maris, J.M.; Keir, S.T.; Morton, C.L.; Reynolds, C.P.; Kang, M.H.; Arts, J.; Bashir, T.; Janicot, M.; Kurmasheva, R.T.; Houghton, P.J. Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr. Blood Cancer, 2012, 59(2), 329-332.
281. Koblish, H.K.; Zhao, S.; Franks, C.F.; Donatelli, R.R.; Tominovich, R.M.; LaFrance, L.V.; Leonard, K.A.; Gushue, J.M.; Parks, D.J.; Calvo, R.R.; Milkiewicz, K.L.; Marugan, J.J.; Raboisson, P.; Cummings, M.D.; Grasberger, B.L.; Johnson, D.L.; Lu, T.; Molloy, C.J.; Maroney, A.C. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Ther., 2006, 5(1), 160-169.
282. Wilson, J.M.; Henderson, G.; Black, F.; Sutherland, A.; Ludwig, R.L.; Vousden, K.H.; Robins, D.J. Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells. Bioorg. Med. Chem., 2007, 15(1), 77-86.
283. Hardcastle, I.R.; Liu, J.; Valeur, E.; Watson, A.; Ahmed, S.U.; Blackburn, T.J.; Bennaceur, K.; Clegg, W.; Drummond, C.; Endicott, J.A.; Golding, B.T.; Griffin, R.J.; Gruber, J.; Haggerty, K.; Harrington, R.W.; Hutton, C.; Kemp, S.; Lu, X.; McDonnell, J.M.; Newell, D.R.; Noble, M.E.; Payne, S.L.; Revill, C.H.; Riedinger, C.; Xu, Q.; Lunec, J. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structureactivity studies leading to improved potency. J. Med. Chem., 2011, 54(5), 1233-1243.
284. Rothweiler, U.; Czarna, A.; Krajewski, M.; Ciombor, J.; Kalinski, C.; Khazak, V.; Ross, G.; Skobeleva, N.; Weber, L.; Holak, T.A. Isoquinolin-1-one inhibitors of the MDM2-p53 interaction. ChemMedChem, 2008, 3(7), 1118-1128.
285. Zhuang, C.; Miao, Z.; Zhu, L.; Dong, G.; Guo, Z.; Wang, S.; Zhang, Y.; Wu, Y.; Yao, J.; Sheng, C.; Zhang, W. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction. J. Med. Chem., 2012, 55(22), 9630-9642.
286. Leao, M.; Pereira, C.; Bisio, A.; Ciribilli, Y.; Paiva, A.M.; Machado, N.; Palmeira, A.; Fernandes, M.X.; Sousa, E.; Pinto, M.; Inga, A.; Saraiva, L. Discovery of a new small-molecule inhibitor of p53-MDM2 interaction using a yeast-based approach. Biochem. Pharmacol., 2013, 85(9), 1234-1245.
287. Lucas, B.S.; Fisher, B.; McGee, L.R.; Olson, S.H.; Medina, J.C.; Cheung, E. An expeditious synthesis of the MDM2-p53 inhibitor AM-8553. J. Am. Chem. Soc., 2012, 134(30), 12855-12860.
288. Zhang, R.; Mayhood, T.; Lipari, P.; Wang, Y.; Durkin, J.; Syto, R.; Gesell, J.; McNemar, C.; Windsor, W. Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction. Analytical Biochem., 2004, 331(1), 138-146.
289. Miyazaki, M.; Naito, H.; Sugimoto, Y.; Yoshida, K.; Kawato, H.; Okayama, T.; Shimizu, H.; Miyazaki, M.; Kitagawa, M.; Seki, T.; Fukutake, S.; Shiose, Y.; Aonuma, M.; Soga, T. Synthesis and evaluation of novel orally active p53-MDM2 interaction inhibitors. Bioorg. Med. Chem., 2013, 21(14), 4319-4331.
290. Wang, W.; Lv, D.; Qiu, N.; Zhang, L.; Hu, C.; Hu, Y. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2. Bioorg. Med. Chem., 2013, 21(11), 2886-2894.
291. Wang, W.; Shangguan, S.; Qiu, N.; Hu, C.; Zhang, L.; Hu, Y. Design, synthesis and biological evaluation of novel 3,4,5- trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1. Bioorg. Med. Chem., 2013, 21(11), 2879-2885.
292. Gonzalez-Lopez de Turiso, F.; Sun, D.; Rew, Y.; Bartberger, M.D.; Beck, H.P.; Canon, J.; Chen, A.; Chow, D.; Correll, T.L.; Huang, X.; Julian, L.D.; Kayser, F.; Lo, M.C.; Long, A.M.; McMinn, D.; Oliner, J.D.; Osgood, T.; Powers, J.P.; Saiki, A.Y.; Schneider, S.; Shaffer, P.; Xiao, S.H.; Yakowec, P.; Yan, X.; Ye, Q.; Yu, D.; Zhao, X.; Zhou, J.; Medina, J.C.; Olson, S.H. Rational design and binding mode duality of MDM2-p53 inhibitors. J. Med. Chem., 2013, 56(10), 4053-4070.
293. Hu, C.; Li, X.; Wang, W.; Zhang, L.; Tao, L.; Dong, X.; Sheng, R.; Yang, B.; Hu, Y. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors. Bioorg. Med. Chem., 2011, 19(18), 5454-5461.
294. Lindstrom, M.S.; Jin, A.; Deisenroth, C.; White Wolf, G.; Zhang, Y. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation. Mol. Cell. Biol., 2007, 27(3), 1056-1068.
295. Sczaniecka, M.; Gladstone, K.; Pettersson, S.; McLaren, L.; Huart, A.S.; Wallace, M. MDM2 protein-mediated ubiquitination of numb protein: identification of a second physiological substrate of MDM2 that employs a dual-site docking mechanism. J. Biol. Chem., 2012, 287(17), 14052-14068.
296. Wang, S.; Zhao, Y.; Bernard, D.; Aguilar, A.; Kumar, S. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics. In Topics in Medicinal Chemistry ed.; Springer Berlin Heidelberg: 2012; Vol. 8.
297. Zhao,Y.; Bernard, D; Wang, S. Small molecule inhibitors of MDM2-p53 and MDMX-p53 interactions as new cancer therapeutics. BioDiscovery, 2013, 8, 4.
298. Azmi, A. S.; Philip, P. A.; Beck, F. W.; Wang, Z.; Banerjee, S.; Wang, S.; Yang, D.; Sarkar, F. H.; Mohammad, R. M. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene, 2011, 30(1), 117-126.
299. Xiong, J.; Yang, Q.; Li, J.; Zhou, S. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer. Angiogenesis, 2013, Aug 2. [Epub ahead of Print].
300. Busuttil, V.; Droin, N.; McCormick, L.; Bernassola, F.; Candi, E.; Melino, G.; Green, D.R. NF-kappaB inhibits T-cell activationinduced, p73-dependent cell death by induction of MDM2. Proc. Natl. Acad. Sci. U S A., 2010, 107(42), 18061-18066.
301. Truong, A.H.; Cervi, D.; Lee, J.; Ben-David, Y. Direct transcriptional regulation of MDM2 by Fli-1. Oncogene, 2005, 24(6), 962-969.
302. Ries, S.; Biederer, C.; Woods, D.; Shifman, O.; Shirasawa, S.; Sasazuki, T.; McMahon, M.; Oren, M.; McCormick, F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell, 2000, 103(2), 321-330.
303. Zhang, X.; Zhang, Z.; Cheng, J.; Li, M.; Wang, W.; Xu, W.; Wang, H.; Zhang, R. Transcription factor NFAT1 activates the mdm2 oncogene independent of p53. J. Biol. Chem., 2012, 287(36), 30468-30476.
304. Saha, M.N.; Jiang, H.; Jayakar, J.; Reece, D.; Branch, D.R.; Chang, H. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol. Ther., 2010, 9(11), 936-944.
305. Jin, L.; Tabe, Y.; Kojima, K.; Zhou, Y.; Pittaluga, S.; Konopleva, M.; Miida, T.; Raffeld, M. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett., 2010, 299(2), 161-170.
306. Graves, B.; Thompson, T.; Xia, M.; Janson, C.; Lukacs, C.; Deo, D.; Di Lello, P.; Fry, D.; Garvie, C.; Huang, K.S.; Gao, L.; Tovar, C.; Lovey, A.; Wanner, J.; Vassilev, L.T. Activation of the p53 pathway by small-molecule- induced MDM2 and MDMX dimerization. Proc. Natl. Acad. Sci. U S A., 2012, 109(29), 11788-11793.